This is a working overview of 脂肪酸侧链, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-01. Anything still debated is marked as such rather than presented as settled.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
The right 'to seek, receive and impart information and ideas of all kinds, regardless of frontiers' is a basic part of freedom of expression, as much as the right against 'arbitrary or unlawful interference with [our] privacy, family, home or correspondence', whether interference is by business, government or anyone else. Communication networks, from the post to telephone lines to the internet, are crucial for friends, families, business and government, and EU law sets standards for their construction and use. For example, the Postal Services Directive 1997 article 3 requires 'universal service' at minimum standards by the main postal provider. For mobile phone access anywhere in the EU, the Roaming Regulation 2022 eliminates extra charges for mobile calls, texts and data when abroad in other member states, and wholesale charges must be fair. To ensure internet service providers do not slow speeds for some websites to gain unfair profit, the Net Neutrality Regulation 2015 states providers 'of internet access services shall treat all traffic equally' but this shall not prevent 'reasonable traffic management measures'.
Fernández had in April 2023 announced that he, despite being eligible for a second, would not seek re-election. The Lula government openly supported the candidacy of governing coalition Sergio Massa, defeated in the second round by the libertarian Javier Milei, who during the campaign referred to Lula as "communist" and "corrupt". Lula did not call to congratulate Milei, limiting himself to publishing a protocol message on social media in which the Milei's name was absent. The minister of the Secretariat of Social Communication, Paulo Pimenta, suggested that only after Milei "calls to apologize" would there be dialogue between him and Lula. Days after the victory, Milei sent a letter to Lula, received by Mauro Vieira, in which Milei deviated from his harsh campaign rhetoric and invited Lula to his inauguration. Despite this, Lula did not participate, acting in the same way as Bolsonaro in 2019, who campaigned against Fernández, sending diplomat Mauro Vieira.
The nociceptin opioid peptide receptor (NOP), also known as the nociceptin/orphanin FQ (N/OFQ) receptor or kappa-type 3 opioid receptor, is a protein that in humans is encoded by the OPRL1 (opioid receptor-like 1) gene. The nociceptin receptor is a member of the opioid subfamily of G protein-coupled receptors whose natural ligand is the 17 amino acid neuropeptide known as nociceptin (N/OFQ). This receptor is involved in the regulation of numerous brain activities, particularly instinctive and emotional behaviors. Antagonists targeting NOP are under investigation for their role as treatments for depression and Parkinson's disease, whereas NOP agonists have been shown to act as powerful, non-addictive painkillers in non-human primates. Although NOP shares high sequence identity (~60%) with the ‘classical’ opioid receptors μ-OP (MOP), κ-OP (KOP), and δ-OP (DOP), it possesses little or no affinity for opioid peptides or morphine-like compounds. Likewise, classical opioid receptors possess little affinity towards NOP's endogenous ligand nociceptin, which is structurally related to dynorphin A.
In crystallography, polymorphism is the phenomenon where a compound can crystallize into more than one crystal structure; in the case of elements the term allotropy is sometimes used. An example of polymorphism is titanium dioxide (TiO2), which occurs in four known natural polymorphic forms (minerals with the same composition but different structure): brookite (orthorhombic), akaogiite (monoclinic), anatase (tetragonal) and rutile (tetragonal). Eilhard Mitscherlich discovered polymorphism ("dimorphism") in his studies of sodium phosphate (1821) and sulphur (1823). In the 1830s the development of the microscope enhanced observations of polymorphism and aided Moritz Ludwig Frankenheim's studies. Frankenheim was able to demonstrate methods to induce crystal phase changes, for example the use of solvents or physical scratching, and formally summarized his findings on the nature of polymorphism. Soon after, the more sophisticated polarized light microscope came into use, and it provided better visualization of crystalline phases allowing crystallographers to distinguish between different polymorphs. The hot stage was invented and fitted to a polarized light microscope by Otto Lehmann in about 1877. This invention helped crystallographers determine melting points and observe polymorphic transitions. The first polymorphic organic substance, benzamide, was discovered by Friedrich Wöhler and Justus von Liebig in 1832. In 1870 Paul Groth defined wikt:morphotropy as the state of two crystals whose similar physical structure is due to similar chemical composition.
Sources: en.wikipedia.org
In the 1870s, Paul Ehrlich developed a staining technique using a combination of an acidic and basic dye that could distinguish different types of white blood cells and allow red blood cell morphology to be examined. Dmitri Leonidovich Romanowsky improved on this technique in the 1890s, using a mixture of eosin and aged methylene blue to produce a wide range of hues not present when either of the stains was used alone. This became the basis for Romanowsky staining, the technique still used to stain blood smears for manual review. The first techniques for measuring hemoglobin were devised in the late 19th century, and involved visual comparisons of the colour of diluted blood against a known standard. Attempts to automate this process using spectrophotometry and colorimetry were limited by the fact that hemoglobin is present in the blood in many different forms, meaning that it could not be measured at a single wavelength. In 1920, a method to convert the different forms of hemoglobin to one stable form (cyanmethemoglobin or hemiglobincyanide) was introduced, allowing hemoglobin levels to be measured automatically. The cyanmethemoglobin method remains the reference method for hemoglobin measurement and is still used in many automated hematology analyzers. Maxwell Wintrobe is credited with the invention of the hematocrit test. In 1929, he undertook a PhD project at the University of Tulane to determine normal ranges for red blood cell parameters, and invented a method known as the Wintrobe hematocrit.
Using the alcohol in large excess (i.e., as a solvent). Using a dehydrating agent: sulfuric acid not only catalyzes the reaction but sequesters water (a reaction product). Other drying agents such as molecular sieves are also effective. Removal of water by physical means such as distillation as a low-boiling azeotrope with toluene, in conjunction with a Dean-Stark apparatus. Reagents are known that drive the dehydration of mixtures of alcohols and carboxylic acids. One example is the Steglich esterification, which is a method of forming esters under mild conditions. The method is popular in peptide synthesis, where the substrates are sensitive to harsh conditions like high heat. DCC (dicyclohexylcarbodiimide) is used to activate the carboxylic acid to further reaction. 4-Dimethylaminopyridine (DMAP) is used as an acyl-transfer catalyst.
== Mutation effects == A number of human diseases arise from mutations in VWA domains. The domain is named after the von Willebrand factor (VWF) type C repeat which is found in multidomain protein/multifunctional proteins involved in maintaining homeostasis. For the von Willebrand factor the duplicated VWFC domain is thought to participate in oligomerization, but not in the initial dimerization step. The presence of this region in a number of other complex-forming proteins points to the possible involvement of the VWFC domain in complex formation.
Sources: en.wikipedia.org
==== Cosmetic surgery ==== Content promoting cosmetic surgery is popular on TikTok and has spawned several viral trends on the platform. In December 2021, Plastic and Reconstructive Surgery, the journal of the American Society of Plastic Surgeons, published an article about the popularity of some plastic surgeons on TikTok. In the article, it was noted that plastic surgeons were some of the earliest adopters of social media in the medical field and many had been recognized as influencers on the platform. The article published stats about the most popular plastic surgeons on TikTok up to February 2021 and at the time, five different plastic surgeons had surpassed 1 million followers on the platform. In 2021, it was reported that a trend known as the #NoseJobCheck trend was going viral on TikTok. TikTok content creators used a specific audio on their videos while showing how their noses looked before and after having their rhinoplasty surgeries. By January 2021, the hashtag #nosejob had accumulated 1.6 billion views, #nosejobcheck had accumulated 1 billion views, and the audio used in the #NoseJobCheck trend had been used in 120,000 videos. In 2020, Charli D'Amelio, the most-followed person on TikTok at the time, also made a #NoseJobCheck video to show the results of her surgery to repair a broken nose. In April 2022, NBC News reported that surgeons were giving influencers on the platform discounted or free cosmetic surgeries in order to advertise the procedures to their audiences.
== Somatostatin receptor agonists versus antagonists in radiolabelling == Agonists of the somatostatin receptor had been long established as an imaging agent, with the first agonist Ga-DOTATOC coming out in 2001, which is based on a radiolabeled somatostatin receptor agonist drug octreotide, and further developments were based on its structure. Agonists share the characteristic of being uptaken into tumor cells, and degraded intracellularly. Antagonists, while not widely absorbed into the tumor cells, can bind to a wider range of receptors as they can bind to the receptors regardless if the receptors are activated or inactivated. They thus are more sensitive to neuroendocrine tumors. Another study noted the antagonists showed lowered internalization into tumors, cleared from the blood quickly, and had a higher binding to tumors, which were noted to be properties benefitting its use over agonists in detecting metastatic tumors. A head-to-head study of the gallium-containing compounds, where the Ga-NODAGA-JR11 antagonist and Ga-DOTATOC agonist are directly compared, showed that Ga-NODAGA-JR11 had higher hepatic metastatic tumor detection rate and lesion sensitivity than Ga-DOTATOC. Another head-to-head study of lutetium containing compound found the antagonist Lu-DOTA-JR11 bound with the receptors more quickly, had a longer retention time and unbound more slowly than the Lu-DOTA-TATE agonist.
Powdered milk is a common item in UN food aid supplies, fallout shelters, warehouses, and wherever fresh milk is not a viable option. It is frequently used in the manufacture of infant formula. Like other dry foods, it is considered nonperishable and is favored by survivalists, hikers, and others requiring nonperishable, easy-to-prepare food. It is widely used in many developing countries because of reduced transport and storage costs (reduced bulk and weight, no refrigerated vehicles). Because of its resemblance to cocaine and other drugs, powdered milk is sometimes used in filmmaking as a non-toxic prop that may be insufflated.
Thallium is the heaviest stable element in group 13 of the periodic table. At the bottom of the periodic table, the inert-pair effect is quite strong, because of the relativistic stabilisation of the 6s orbital and the decreasing bond energy as the atoms increase in size so that the amount of energy released in forming two more bonds is not worth the high ionisation energies of the 6s electrons. It displays the +1 oxidation state that all the known alkali metals display, and thallium compounds with thallium in its +1 oxidation state closely resemble the corresponding potassium or silver compounds stoichiometrically due to the similar ionic radii of the Tl+ (164 pm), K+ (152 pm) and Ag+ (129 pm) ions. It was sometimes considered an alkali metal in continental Europe (but not in England) in the years immediately following its discovery, and was placed just after caesium as the sixth alkali metal in Dmitri Mendeleev's 1869 periodic table and Julius Lothar Meyer's 1868 periodic table. Mendeleev's 1871 periodic table and Meyer's 1870 periodic table put thallium in its current position in the boron group and left the space below caesium blank. However, thallium also displays the oxidation state +3, which no known alkali metal displays (although ununennium, the undiscovered seventh alkali metal, is predicted to possibly display the +3 oxidation state). The sixth alkali metal is now considered to be francium.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.